Literature DB >> 8385442

Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years.

N Nagasue1, H Kohno, Y C Chang, H Taniura, A Yamanoi, M Uchida, T Kimoto, Y Takemoto, T Nakamura, H Yukaya.   

Abstract

OBJECTIVE: This study analyzed the results in 229 patients with primary hepatocellular carcinoma (HCC) who were treated by radical hepatic resection in the past 11 years. SUMMARY BACKGROUND DATA: Due to marked advances in diagnostic and therapeutic methods, the therapeutic strategy for HCC has changed significantly. However, there are still many problems to be solved when hepatic resection is to be performed for HCC associated with chronic liver disease. A satisfactory result may be possible only when all of accurate operative indication, skillful surgical technique, and sophisticated postoperative management are met.
METHODS: There were 188 men and 41 women. Age ranged from 32 to 79 years averaging 60.8. Underlying cirrhosis of the liver was found in 177 patients, and chronic hepatitis was found in 47 instances. Before surgery, 114 patients had 157 associated conditions; diabetes mellitus in 66, esophageal varices in 42, cholelithiasis in 22, peptic ulcer in 12, and miscellaneous in 15 cases. In addition to various types of hepatic resection, 69 patients underwent concomitant operations such as cholecystectomy, the Warren shunt, splenectomy, partial gastrectomy, and so forth.
RESULTS: The 30-day (operative) mortality rate was 7.0%, and there were eight additional late deaths (3.5%). Child's class, bromosulphalein (BSP) test, and the estimated blood loss during surgery were good predictors for operative death. The cumulative 5- and 10-year survival rates for all patients were 26.4% and 19.4%, respectively. At present, 110 patients are alive; 2 more than 10 years and 21 more than 5 years. Younger age, absence of cirrhosis, smaller tumor, and postoperative chemotherapy were associated with increased survival.
CONCLUSIONS: The results of hepatic resection in 229 patients with HCC were analyzed. Child's class, BSP test, and blood loss during surgery were good predictors for operative death. The 5- and 10-year survival rates were 26.4% and 19.4%, respectively. Age, liver cirrhosis, tumor size, and postoperative chemotherapy were prognostic factors. Multidisciplinary approach with liver resection, postoperative chemotherapy, and liver transplantation will be a realistic direction for the surgical treatment of HCC in future.

Entities:  

Mesh:

Year:  1993        PMID: 8385442      PMCID: PMC1242804          DOI: 10.1097/00000658-199304000-00009

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  30 in total

1.  Liver resections in cirrhotic patients: a Western experience.

Authors:  H Bismuth; D Houssin; J Ornowski; F Meriggi
Journal:  World J Surg       Date:  1986-04       Impact factor: 3.352

2.  Second hepatic resection for recurrent hepatocellular carcinoma.

Authors:  N Nagasue; H Yukaya; Y Ogawa; Y Sasaki; Y C Chang; K Niimi
Journal:  Br J Surg       Date:  1986-06       Impact factor: 6.939

3.  Results in 107 hepatic lobectomies with a preliminary report on the use of a clamp to reduce blood loss.

Authors:  T Y Lin
Journal:  Ann Surg       Date:  1973-04       Impact factor: 12.969

4.  The surgical management of primary carcinoma of the liver.

Authors:  N W Lee; J Wong; G B Ong
Journal:  World J Surg       Date:  1982-01       Impact factor: 3.352

5.  Acute portal vein thrombosis after right hepatic lobectomy: successful treatment by thrombectomy.

Authors:  Y Jaffe; N J Lygidakis; L H Blumgart
Journal:  Br J Surg       Date:  1982-04       Impact factor: 6.939

6.  Hepatic resection for hepatocellular carcinoma. Clinical features and long-term prognosis.

Authors:  T Nagao; S Inoue; S Goto; T Mizuta; Y Omori; N Kawano; Y Morioka
Journal:  Ann Surg       Date:  1987-01       Impact factor: 12.969

7.  Surgical treatment of 109 patients with symptomatic and asymptomatic hepatocellular carcinoma.

Authors:  C S Lee; J L Sung; L Y Hwang; J C Sheu; D S Chen; T Y Lin; R P Beasley
Journal:  Surgery       Date:  1986-04       Impact factor: 3.982

8.  Treatment of fibrolamellar hepatoma with partial or total hepatectomy and transplantation of the liver.

Authors:  T E Starzl; S Iwatsuki; B W Shaw; M A Nalesnik; D C Farhi; D H Van Thiel
Journal:  Surg Gynecol Obstet       Date:  1986-02

9.  Major hepatic resection. A 25-year experience.

Authors:  H H Thompson; R K Tompkins; W P Longmire
Journal:  Ann Surg       Date:  1983-04       Impact factor: 12.969

10.  Regeneration of human liver after hepatic lobectomy studied by repeated liver scanning and repeated needle biopsy.

Authors:  T Y Lin; C S Lee; C C Chen; K Y Liau; W S Lin
Journal:  Ann Surg       Date:  1979-07       Impact factor: 12.969

View more
  55 in total

1.  Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib.

Authors:  Giovanni Abbadessa; Lorenza Rimassa; Tiziana Pressiani; Cynthia Carrillo-Infante; Emanuele Cucchi; Armando Santoro
Journal:  World J Gastroenterol       Date:  2011-05-21       Impact factor: 5.742

Review 2.  Systematic review of actual 10-year survival following resection for hepatocellular carcinoma.

Authors:  Annelise M Gluer; Nicholas Cocco; Jerome M Laurence; Emma S Johnston; Michael J Hollands; Henry C C Pleass; Arthur J Richardson; Vincent W T Lam
Journal:  HPB (Oxford)       Date:  2012-02-28       Impact factor: 3.647

3.  Factors associated with disease survival after surgical resection in Chinese patients with hepatocellular carcinoma.

Authors:  Li Qiang; Li Huikai; Kelly Butt; P Peter Wang; Xishan Hao
Journal:  World J Surg       Date:  2006-03       Impact factor: 3.352

4.  Safe and feasible inflow occlusion in laparoscopic liver resection.

Authors:  Akihiro Cho; Hiroshi Yamamoto; Matsuo Nagata; Nobuhiro Takiguchi; Hideaki Shimada; Osamu Kainuma; Hiroaki Souda; Hisashi Gunji; Akinari Miyazaki; Atsushi Ikeda; Ikuko Matsumoto
Journal:  Surg Endosc       Date:  2008-12-31       Impact factor: 4.584

5.  Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma.

Authors:  C Rabe; T Pilz; C Klostermann; M Berna; H H Schild; T Sauerbruch; W H Caselmann
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

6.  Hepatocellular Carcinoma in Transplantable Child-Pugh A Cirrhotics: Should Cost Affect Resection vs Transplantation?

Authors:  Theodoros Michelakos; Dimitrios Xourafas; Motaz Qadan; Rafael Pieretti-Vanmarcke; Lei Cai; Madhukar S Patel; Joel T Adler; Fermin Fontan; Usama Basit; Parsia A Vagefi; Nahel Elias; Kenneth K Tanabe; David Berger; Heidi Yeh; James F Markmann; David C Chang; Cristina R Ferrone
Journal:  J Gastrointest Surg       Date:  2018-09-14       Impact factor: 3.452

7.  Transcript AA454543 is a novel prognostic marker for hepatocellular carcinoma after curative partial hepatectomy.

Authors:  Siu Tim Cheung; Jenny C Y Ho; Ka Ling Leung; Xin Chen; Daniel Y T Fong; Samuel So; Sheung Tat Fan
Journal:  Neoplasia       Date:  2005-02       Impact factor: 5.715

8.  Preoperative galactose elimination capacity predicts complications and survival after hepatic resection.

Authors:  Claudio A Redaelli; Jean-François Dufour; Markus Wagner; Martin Schilling; Jürg Hüsler; Lukas Krähenbühl; Markus W Büchler; Jürg Reichen
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

Review 9.  Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review.

Authors:  Maria-Aggeliki Kalogeridi; Anna Zygogianni; George Kyrgias; John Kouvaris; Sofia Chatziioannou; Nikolaos Kelekis; Vassilis Kouloulias
Journal:  World J Hepatol       Date:  2015-01-27

Review 10.  Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis.

Authors:  Bethany B Barone; Hsin-Chieh Yeh; Claire F Snyder; Kimberly S Peairs; Kelly B Stein; Rachel L Derr; Antonio C Wolff; Frederick L Brancati
Journal:  Diabetes Care       Date:  2010-04       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.